Trump Disclosure Shows Corcept Buy Before FDA Approval

By: Quiver EventTracker

Posted: 1 month, 2 weeks ago / July 20, 2026 5:37 p.m. UTC

CORT

A public financial disclosure by President Donald Trump shows a $50,001-to-$100,000 purchase of Corcept Therapeutics stock on March 3rd, 2026, weeks before the FDA approved Corcept’s ovarian-cancer drug Lifyorli on March 25.

Disclosure: Quiver Quantitative lists the Corcept purchase as a Trump transaction dated March 3rd and disclosed May 13. Source

Reporting rules: OGE Form 278-T covers securities purchases, sales or exchanges over $1,000 made on behalf of the filer, spouse or dependent child. Source

FDA action: The FDA approved Lifyorli with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Source

Relevant Companies

Corcept Therapeutics (CORT): Directly impacted by Lifyorli approval and related investor attention.

Add Quiver Quantitative to your preferred sources on Google

Suggested Articles

Put Quiver's data inside your AI Model at 50% off Sept. 5, 2026 7 p.m. UTC

U.S. Strikes Three Iranian Oil Tankers After Missile Attacks Sept. 5, 2026 1:55 p.m. UTC

NHTSA Opens Investigation Into Tesla Cybercab Safety Compliance Sept. 4, 2026 2:30 p.m. UTC